Transanal total mesorectal excision (TaTME) versus laparoscopic TME for MRI-defined low rectal cancer: a propensity score-matched analysis of oncological outcomes.


Journal

Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653

Informations de publication

Date de publication:
08 2019
Historique:
received: 18 03 2018
accepted: 11 10 2018
pubmed: 24 10 2018
medline: 28 4 2020
entrez: 24 10 2018
Statut: ppublish

Résumé

While a shift to minimally invasive techniques in rectal cancer surgery has occurred, non-inferiority of laparoscopy in terms of oncological outcomes has not been definitely demonstrated. Transanal total mesorectal excision (TaTME) has been pioneered to potentially overcome difficulties experienced when operating with a pure abdominal approach deep down in the pelvis. This study aimed to compare short-term oncological results of TaTME versus laparoscopic TME (lapTME), based on a strict anatomical definition for low rectal cancer on MRI. From June 2013, all consecutive TaTME cases were included and compared to lapTME in a single institution. Propensity score-matching was performed for nine relevant factors. Primary outcome was resection margin involvement (R1), secondary outcomes included intra- and post-operative outcomes. After matching, forty-one patients were included in each group; no significant differences were observed in patient and tumor characteristics. The resection margin was involved in 5 cases (12.2%) in the laparoscopic group, versus 2 (4.9%) TaTME cases (P = 0.432). The TME specimen quality was complete in 84.0% of the laparoscopic cases and in 92.7% of the TaTME cases (P = 0.266). Median distance to the circumferential resection margin (CRM) was 5 mm in lapTME and 10 mm in TaTME (P = 0.065). Significantly more conversions took place in the laparoscopic group, 9 (22.0%) compared to none in the TaTME group (P < 0.001). Other clinical outcomes did not show any significant differences between the two groups. This is the first study to compare results of TaTME with lapTME in a highly selected patient group with MRI-defined low rectal tumors. A significant decrease in R1 rate could not be demonstrated, although conversion rate was significantly lower in this TaTME cohort.

Sections du résumé

BACKGROUND
While a shift to minimally invasive techniques in rectal cancer surgery has occurred, non-inferiority of laparoscopy in terms of oncological outcomes has not been definitely demonstrated. Transanal total mesorectal excision (TaTME) has been pioneered to potentially overcome difficulties experienced when operating with a pure abdominal approach deep down in the pelvis. This study aimed to compare short-term oncological results of TaTME versus laparoscopic TME (lapTME), based on a strict anatomical definition for low rectal cancer on MRI.
METHODS
From June 2013, all consecutive TaTME cases were included and compared to lapTME in a single institution. Propensity score-matching was performed for nine relevant factors. Primary outcome was resection margin involvement (R1), secondary outcomes included intra- and post-operative outcomes.
RESULTS
After matching, forty-one patients were included in each group; no significant differences were observed in patient and tumor characteristics. The resection margin was involved in 5 cases (12.2%) in the laparoscopic group, versus 2 (4.9%) TaTME cases (P = 0.432). The TME specimen quality was complete in 84.0% of the laparoscopic cases and in 92.7% of the TaTME cases (P = 0.266). Median distance to the circumferential resection margin (CRM) was 5 mm in lapTME and 10 mm in TaTME (P = 0.065). Significantly more conversions took place in the laparoscopic group, 9 (22.0%) compared to none in the TaTME group (P < 0.001). Other clinical outcomes did not show any significant differences between the two groups.
CONCLUSION
This is the first study to compare results of TaTME with lapTME in a highly selected patient group with MRI-defined low rectal tumors. A significant decrease in R1 rate could not be demonstrated, although conversion rate was significantly lower in this TaTME cohort.

Identifiants

pubmed: 30350103
doi: 10.1007/s00464-018-6530-4
pii: 10.1007/s00464-018-6530-4
pmc: PMC6647375
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2459-2467

Références

Ann Surg. 2010 May;251(5):807-18
pubmed: 20395841
Surg Endosc. 2014 Dec;28(12):3494-9
pubmed: 24972923
Br J Surg. 2004 Aug;91(8):1040-5
pubmed: 15286968
Tech Coloproctol. 2016 Jul;20(7):467-73
pubmed: 27178183
Tech Coloproctol. 2016 Aug;20(8):537-44
pubmed: 26993638
J Clin Oncol. 2008 Jan 10;26(2):303-12
pubmed: 18182672
Eur J Surg Oncol. 2009 Dec;35(12):1273-9
pubmed: 19615848
Ann Surg. 2017 Jul;266(1):111-117
pubmed: 27735827
Colorectal Dis. 2006 Sep;8 Suppl 3:30-2
pubmed: 16813590
JAMA. 2015 Oct 6;314(13):1356-63
pubmed: 26441180
Ann Surg. 2013 Apr;257(4):665-71
pubmed: 23333881
Eur J Surg Oncol. 2016 Dec;42(12):1841-1850
pubmed: 27697315
Lancet. 2005 May 14-20;365(9472):1718-26
pubmed: 15894098
Surg Endosc. 2016 Aug;30(8):3210-5
pubmed: 26537907
Colorectal Dis. 2014 Mar;16(3):173-8
pubmed: 24267315
Arch Surg. 1998 Aug;133(8):894-9
pubmed: 9711965
Ann Surg. 2017 Nov;266(5):870-877
pubmed: 28746154
Lancet. 2009 Mar 7;373(9666):821-8
pubmed: 19269520
Colorectal Dis. 2010 Jan;12(1):37-43
pubmed: 19175624
Ann Surg. 2016 Apr;263(4):751-60
pubmed: 25822672
Ann Surg. 2019 Apr;269(4):700-711
pubmed: 29315090
Dis Colon Rectum. 2018 Jul;61(7):809-816
pubmed: 29771810
J Laparoendosc Adv Surg Tech A. 2018 Apr;28(4):365-369
pubmed: 29190178
Ann Surg Oncol. 2016 Apr;23(4):1169-76
pubmed: 26597369
Lancet. 1986 Nov 1;2(8514):996-9
pubmed: 2430152
Dis Colon Rectum. 2001 Mar;44(3):315-21
pubmed: 11289275
Lancet Oncol. 2013 Mar;14(3):210-8
pubmed: 23395398
Br J Surg. 2007 Dec;94(12):1555-61
pubmed: 17668915
Ann Surg. 2003 Mar;237(3):335-42
pubmed: 12616116
Tech Coloproctol. 2016 Dec;20(12):811-824
pubmed: 27853973
Langenbecks Arch Surg. 2015 Dec;400(8):945-59
pubmed: 26497544
JAMA. 2015 Oct 6;314(13):1346-55
pubmed: 26441179
Colorectal Dis. 2016 Jan;18(1):51-8
pubmed: 26603786
JAMA. 2017 Oct 24;318(16):1569-1580
pubmed: 29067426
Ann Surg. 2013 Jan;257(1):108-13
pubmed: 22968068
J Clin Oncol. 2005 Dec 20;23(36):9257-64
pubmed: 16361623
Ann Surg. 2015 Feb;261(2):221-7
pubmed: 25185463
Colorectal Dis. 2016 Dec;18(12):1154-1161
pubmed: 27218423
Surg Endosc. 2008 Dec;22(12):2625-30
pubmed: 18297346

Auteurs

Sapho Xenia Roodbeen (SX)

Department Surgery, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Marta Penna (M)

Department of Colorectal Surgery, Churchill Hospital, Oxford University Hospital NHS Foundation Trust, Oxford, UK.

Hugh Mackenzie (H)

Department of Surgery and Cancer, Imperial College London, London, UK.

Miranda Kusters (M)

Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands.

Andrew Slater (A)

Department of Radiology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Oliver M Jones (OM)

Department of Colorectal Surgery, Churchill Hospital, Oxford University Hospital NHS Foundation Trust, Oxford, UK.

Ian Lindsey (I)

Department of Colorectal Surgery, Churchill Hospital, Oxford University Hospital NHS Foundation Trust, Oxford, UK.

Richard J Guy (RJ)

Department of Colorectal Surgery, Churchill Hospital, Oxford University Hospital NHS Foundation Trust, Oxford, UK.

Chris Cunningham (C)

Department of Colorectal Surgery, Churchill Hospital, Oxford University Hospital NHS Foundation Trust, Oxford, UK.

Roel Hompes (R)

Department Surgery, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. roelhompes@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH